Table 3. Differentially abundant plasma and urine peptides (900–3000 m/z) correlating with cervical cancer, CIN 2 or control samples.

No.	Peptide Mass (m/z)	Sample Set	Protein Identified	Distribution in Samples
1	904.53	FX3a	kininogen L,high MW	Absent in Control; Cerv Ca = CIN 2
2	1097.49	Urine	–	CIN 2 = Control>Cerv Ca
3	1126.503	Urine	alpha-1 type I collagen	CIN 2> Cerv Ca >Control
4	1192.67	FX3a	–	Absent in Control; Cerv Ca = CIN 2
5	1236.56	Urine	alpha-1 type I collagen	CIN 2> Control>Cerv Ca
6	1425.65	Urine	alpha-1 type XVII collagen	Absent in Control; CIN 2>Cerv Ca
7	1524.71	Urine	–	CIN 2> Cerv Ca = Control
8	1530.91	FX1b	–	Absent in CIN 2; Cerv Ca = Control
9	1587.97	Urine	–	CIN 2> Control>Cerv Ca
10	1746.78	FX1b, FX2c	–	Control>Cerv Ca = CIN 2
11	1943.93	FX2c	kininogen L,high MW	Control
12	2080.98	FX2c	kininogen L,high MW	Control
13	2209.06	FX2c	kininogen L,high MW	Control>Cerv Ca = CIN 2
14	2228.05	FX2c	–	Absent in CIN 2; Control>Cerv Ca
15	2271.13	FX2c	–	Control>Cerv Ca = CIN 2

^a FX3, Fraction 3: peptides released during the immunodepletion of albumin and IgG from plasma.

^b FX1, Fraction 1: freely soluble plasma peptides.

^c FX2, Fraction 2: peptides bound to total plasma proteins.